Kiromic BioPharma, Inc. (NASDAQ:KRBP – Get Free Report) shares fell 2.7% on Thursday . The company traded as low as $0.90 and last traded at $0.90. 340 shares traded hands during mid-day trading, a decline of 93% from the average session volume of 4,613 shares. The stock had previously closed at $0.93.
Kiromic BioPharma Stock Performance
The firm has a market cap of $1.38 million, a price-to-earnings ratio of -0.14 and a beta of 1.87. The business has a 50 day simple moving average of $0.99 and a 200-day simple moving average of $1.52.
About Kiromic BioPharma
Kiromic BioPharma, Inc, a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1.
Read More
- Five stocks we like better than Kiromic BioPharma
- Stock Analyst Ratings and Canadian Analyst Ratings
- 3 Legacy Tech Companies Reemerging as AI LeadersÂ
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for Kiromic BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiromic BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
